MONITOR-GCSF DLBCL subanalysis: Treatment patterns/outcomes with biosimilar filgrastim for chemotherapy-induced/febrile neutropenia prophylaxis
Author:
Affiliation:
1. Department of Hematology-Oncology; University of Barcelona; Barcelona Spain
2. Sandoz Biopharmaceuticals/Hexal AG; Holzkirchen Germany
3. Institut Multidisciplinaire d'Oncologie; Clinique de Genolier; Genolier Switzerland
Funder
Sandoz International GmbH
Publisher
Wiley
Subject
Hematology,General Medicine
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/ejh.13002/fullpdf
Reference26 articles.
1. Ladetto M; ESMO guidelines committee. Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up;Tilly;Ann Oncol,2015
2. Diagnosis and treatment of CD20 negative B cell lymphomas;Katchi;Biomark Res,2017
3. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial;Pettengell;Blood,1992
4. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia;Sehn;J Clin Oncol,2005
5. Rates of febrile neutropenia with pegfilgrastim on same day versus next day of CHOP with or without rituximab;Cheng;Anticancer Drugs,2014
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Perspectives toward biosimilars among oncologists: A Malaysian survey;Journal of Oncology Pharmacy Practice;2022-06-13
2. Side effects of using granulocyte-colony stimulating factors as prophylaxis of febrile neutropenia in cancer patients: A systematic review;Critical Reviews in Oncology/Hematology;2021-01
3. Extrapolation in Practice: Lessons from 10 Years with Biosimilar Filgrastim;BioDrugs;2019-08-22
4. Biosimilars in oncology: A decade of experience with granulocyte colony-stimulating factor and its implications for monoclonal antibodies;Critical Reviews in Oncology/Hematology;2019-07
5. Treatment patterns and outcomes in patients with non‐small cell lung cancer receiving biosimilar filgrastim for prophylaxis of chemotherapy‐induced/febrile neutropaenia: Results from the MONITOR‐GCSF study;European Journal of Cancer Care;2019-04-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3